Boothbay Fund Management’s Medicines Co MDCO Stock Holding History

Boothbay Fund Management’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-8,700	Closed	-$287K	–	964
2018 Q1	$287K	Buy	+8,700	New	+$272K	0.03%	490

Other funds holding MDCO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Boothbay Fund Management's MDCO Position: Q2 2018 in Review

Boothbay Fund Management sold out of Medicines Co (MDCO) in Q2 2018, closing a stake of 8,700 shares — an estimated $287K sold.

Boothbay Fund Management first reported a position in MDCO in Q1 2018 and held it in 1 quarter. The position peaked at $287K in Q1 2018. 188 funds tracked by Wall St. Rank hold MDCO as of Q2 2018.

Boothbay Fund Management reported no remaining Medicines Co position as of Q2 2018 after selling out during the quarter.
Boothbay Fund Management sold 8,700 Medicines Co shares in Q2 2018, an estimated $287K.
Boothbay Fund Management first reported a position in Medicines Co in Q1 2018 and held it in 1 quarter.
Boothbay Fund Management's Medicines Co position peaked at $287K in Q1 2018.
188 funds tracked by Wall St. Rank held Medicines Co as of Q2 2018.

Based on Boothbay Fund Management's 13F filing for Q2 2018, filed 14 Aug 2018.